
Gasporox - Managed for long-term value creation

Redeye comments on Gasporox Q4'22 report which came in lighter than expected. However, our view is that the Company is investing for sustained long-term growth and one quarter should not be viewed in isolation. Overall, we reduce our net sales 2023e-2025e by 17%-20% and reduce our Base case by 20%.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Gasporox - Managed for long-term value creation](#)